Fifty healthcare advocacy organizations have signed onto a letter urging Congress to include incentives for the development of new antibiotics and companion diagnostics in the Prescription Drug User Fee Act, which is up for reauthorization this year.
The letter cites an alarming drop in the number of pharmaceutical companies pursuing large antibiotic research programs, at the same time as the number of patients with essentially untreatable infections is increasing.
